Knights of Columbus Asset Advisors LLC Sells 429 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Knights of Columbus Asset Advisors LLC lessened its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 6.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,193 shares of the company’s stock after selling 429 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Apellis Pharmaceuticals were worth $371,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of APLS. First Horizon Advisors Inc. raised its stake in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after acquiring an additional 265 shares in the last quarter. Covestor Ltd raised its position in Apellis Pharmaceuticals by 564.2% during the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after purchasing an additional 677 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth $38,000. US Bancorp DE grew its position in shares of Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after buying an additional 884 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new position in shares of Apellis Pharmaceuticals during the second quarter valued at $202,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Up 0.0 %

Shares of APLS stock opened at $47.53 on Monday. The stock’s fifty day moving average price is $59.71 and its 200 day moving average price is $57.17. Apellis Pharmaceuticals, Inc. has a 1-year low of $19.83 and a 1-year high of $94.75. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -10.61 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. During the same quarter last year, the company earned ($1.50) earnings per share. The company’s quarterly revenue was up 545.9% on a year-over-year basis. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the sale, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Cedric Francois sold 2,843 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $64.14, for a total value of $182,350.02. Following the completion of the transaction, the chief executive officer now directly owns 317,624 shares in the company, valued at $20,372,403.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 381,011 shares of company stock valued at $23,463,657. Insiders own 7.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Oppenheimer upped their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Robert W. Baird reiterated an “outperform” rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Mizuho reissued a “neutral” rating and set a $60.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Finally, The Goldman Sachs Group lifted their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.93.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).